Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare

Lene Stryhn*, Mathias Bach Larsen, Anna Mejldal, Christian Sibbersen, Dorthe Grüner Nielsen, Bent Nielsen, Anette Søgaard Nielsen, Elsebeth Stenager, Angelina Isabella Mellentin

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Aims: Many patients with alcohol use disorders are challenged by cravings leading to repeated relapses. Both cue exposure therapy (CET) and acamprosate target alcohol cravings and are often combined (CET + acamprosate). The main aim of this study was to investigate whether aftercare treatment consisting of CET combined with acamprosate is equivalent to (A) CET as monotherapy, (B) aftercare as usual (AAU) as monotherapy or (C) AAU combined with acamprosate. Methods: Patients were randomized to receive either CET with urge-specific coping skills (USCS) as aftercare or AAU. Acamprosate prescription data were extracted from patient case records. Alcohol consumption, cravings, and USCS were assessed at pre-aftercare, post-aftercare, and 6-month follow-up. Results: Overall, patients increased their alcohol consumption during and following aftercare treatment, thereby relapsing despite any treatment. However, CET + acamprosate achieved greater abstinence compared to AAU + acamprosate at follow-up (p=.047). CET + acamprosate also reduced number of drinking days (p=.020) and number of days with excessive drinking (p=.020) at post-aftercare, when compared to AAU monotherapy. CET monotherapy increased sensible drinking at post-aftercare compared to AAU monotherapy (p=.045) and AAU + acamprosate (p=.047). Only CET monotherapy showed improvement in cravings, when compared to AAU at follow-up (mean urge level: p=.032; peak urge level: p=.014). Conclusion: The study showed that CET both as monotherapy and combined with acamprosate was superior to AAU monotherapy and AAU + acamprosate in reducing alcohol consumption. Only CET + acamprosate was capable of reducing alcohol consumption in the longer term, indicating that anti-craving medication may not impede CET from exerting an effect on alcohol consumption. Trial registration: ClinicalTrials.gov ID: NCT02298751 (24/11-2014).

OriginalsprogEngelsk
BogserieNordic Journal of Psychiatry
ISSN0803-9488
DOI
StatusE-pub ahead of print - 8. okt. 2021

Bibliografisk note

Publisher Copyright:
© 2021 The Nordic Psychiatric Association.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare'. Sammen danner de et unikt fingeraftryk.

Citationsformater